Incyte (INCY) Expected to Announce Quarterly Earnings on Tuesday

Incyte (NASDAQ:INCY - Get Free Report) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Tuesday, April 29th. Analysts expect Incyte to post earnings of $1.01 per share and revenue of $996.17 million for the quarter.

Incyte (NASDAQ:INCY - Get Free Report) last released its quarterly earnings data on Monday, February 10th. The biopharmaceutical company reported $1.09 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.48). Incyte had a net margin of 0.77% and a return on equity of 0.05%. On average, analysts expect Incyte to post $5 EPS for the current fiscal year and $7 EPS for the next fiscal year.

Incyte Stock Up 0.3 %

NASDAQ INCY traded up $0.19 during trading hours on Friday, reaching $59.16. 1,237,382 shares of the company's stock were exchanged, compared to its average volume of 2,366,718. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.94 and a current ratio of 1.97. Incyte has a one year low of $50.35 and a one year high of $83.95. The company's 50-day moving average is $63.87 and its two-hundred day moving average is $69.05. The company has a market capitalization of $11.45 billion, a price-to-earnings ratio of 219.12, a price-to-earnings-growth ratio of 0.41 and a beta of 0.89.

Insider Buying and Selling at Incyte

In other Incyte news, EVP Sheila A. Denton sold 599 shares of the business's stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $69.99, for a total transaction of $41,924.01. Following the completion of the transaction, the executive vice president now owns 25,848 shares of the company's stock, valued at approximately $1,809,101.52. The trade was a 2.26 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Barry P. Flannelly sold 19,807 shares of the firm's stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $67.69, for a total transaction of $1,340,735.83. Following the completion of the sale, the executive vice president now owns 33,567 shares in the company, valued at approximately $2,272,150.23. The trade was a 37.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 34,475 shares of company stock worth $2,424,751 over the last three months. Corporate insiders own 17.60% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on INCY. Guggenheim cut Incyte from a "buy" rating to a "neutral" rating and set a $92.00 price objective for the company. in a research report on Tuesday, March 18th. Royal Bank of Canada cut their price objective on shares of Incyte from $70.00 to $68.00 and set a "sector perform" rating on the stock in a research report on Tuesday, February 11th. JMP Securities reaffirmed a "market perform" rating on shares of Incyte in a research report on Tuesday, February 11th. Morgan Stanley reduced their price objective on shares of Incyte from $69.00 to $65.00 and set an "equal weight" rating for the company in a research note on Monday, March 24th. Finally, JPMorgan Chase & Co. lowered their target price on Incyte from $70.00 to $68.00 and set a "neutral" rating on the stock in a research report on Monday. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $74.69.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.